GeneDx Holdings Corp. (WGS) key performance indicators and operating metrics (7 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Exome and Genome Test Revenue | 90.6M | FY2026-Q1 |
| Adjusted Total Operating Expenses | 78.1M | FY2026-Q1 |
| Adjusted Gross Margin | 69.00 percent | FY2026-Q1 |
| Total GAAP Operating Expenses | 94.4M | FY2026-Q1 |
| Exome and Genome Test Result Volume | 27.49K | FY2026-Q1 |
| Adjusted Net Income | 4.4M | FY2025-Q4 |
| Exome and Genome Test Results Volume | 25.7K | FY2025-Q3 |
Back to WGS overview · WGS earnings · WGS holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.